New Developments in the Management of Overactive Bladder: Focus on Mirabegron and onabotulinumtoxinA

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s33052
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

OnabotulinumtoxinA for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2014English

Mirabegron: A Beta-3 Agonist for Overactive Bladder

The Consultant Pharmacist
2014English

Pd26-10 Onabotulinumtoxina Provides Early and Consistent Improvements in Overactive Bladder Symptoms and Quality of Life Outcomes in Patients With Overactive Bladder

Journal of Urology
Urology
2017English

Management of Overactive Bladder

2018English

Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2012English

Persistence and Adherence With Mirabegron, a New Beta-3 Receptor Agonist, Versus Antimuscarinics in Overactive Bladder: Early Experience in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study

BMC Urology
MedicineReproductive MedicineUrology
2018English

Mp77-14 Sacral Neuromodulation for Refractory Overactive Bladder After Prior Intravesical Onabotulinumtoxina Treatment.

Journal of Urology
Urology
2016English

Transdermal Oxybutynin: What Role in the Management of Overactive Bladder?

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy